This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XOMA's CEO Discusses Q4 2011 Results - Earnings Call Transcript

XOMA Corporation (XOMA)

Q4 2011 Earnings Call

March 14, 2012; 04:30 pm ET


John Varian - Chief Executive Officer

Dr. Paul Rubin - Vice President & Chief Medical Officer

Fred Kurland - Vice President & Chief Financial Officer

Carol DeGuzman - Senior Director of Investor Relations


Matt Kaplan - Ladenburg Thalmann

Jason Kantor - RBC Capital Markets



Good day ladies and gentlemen and welcome to the XOMA, fourth quarter 2011 financial results conference call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session with instructions following at that time. (Operator Instructions).

I’ll now turn the call over to Carol DeGuzman, Senior Director of Investor Relations. Please begin.

Carol DeGuzman

Thank you operator. Good afternoon everyone. A short while ago we issued a news release, which included our financial results for the period ended December 31, 2011 and a general business update. Our Annual Report and Form 10-K is being filed with the Securities and Exchange Commission this afternoon and each of these documents will be available on our website at Today’s webcast also can be accessed via our website and will be available for replay until the close of business on June 10, 2012.

Leading today’s call is John Varian, XOMA’s Chief Executive Officer, who is joined by Dr. Paul Rubin, our Vice President and Chief Medical Officer and Fred Kurland, our Vice President and Chief Financial Officer.

We wish to remind our listeners that certain statements that will be made today concerning the timing of initiation of clinical trials, availability of clinical trial results, continued sales of approved products, regulatory approval of unapproved product candidates and anticipated levels of cash utilization or that otherwise relate to future periods are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs